

Current COVID-19 clinical trials and studies

The studies listed here are aimed at providing prospective researchers with information about what COVID-related research is already under way in Oxford to avoid potential duplication of effort and to promote collaboration. This list is illustrative - not every study is listed – and it does not include studies of diagnostics.

This information will be updated periodically. Enquires about the status of specific studies or recruitment should be directed to the study team.

[A complete list of studies can be accessed here.](#)

COVID Vaccine-related studies

Phase 1 and 2 studies

Study name	COV001	COV006	COV008	COMCOV 1 and 2
Local Principal Investigator	Prof Brian Angus	Prof Andrew Pollard	Dr Alexander Douglas	Dr Maheshi Ramasamy
Intervention(s)	ChAdOx1 nCoV-19	ChAdOx1 nCoV-19 in children	Intranasal ChAdOx1 nCoV-19	Different combinations of vaccines
Study size	1,090	TBC	30	1,050
Status	In follow-up	Paused	Recruiting by invitation	Recruiting

Phase 3 studies

Study name	COV002	Ensemble 2	Pfizer/BioNTech in pregnant women
Local Principal Investigator	Prof Andrew Pollard	Prof Saul Faust (Southampton)	Christine Jones (Southampton)
Intervention(s)	ChAdOx1 nCoV-19	Janssen COVID vaccine (VAC31518COV3009)	BNT162b2 (Pfizer / BioNTech) vaccine in pregnant women
Study size	12,390	30,000	1,000
Status	In follow-up	Ongoing	Ongoing

Viral challenge study

Study name	COV-CHIM
Local Principal Investigator	Prof Helen McShane
Intervention(s)	COVID viral challenge study
Study size	64
Status	Ongoing

Interventional studies in hospitalised patients (CTIMPS)

Clinical Trial or study evaluating the safety or efficacy of a drug (Investigational Medicinal Product - CTIMP)

Phase 2

Study name	SNG001	CATALYST	ACTT	Almetrine
Local Principal Investigator	Prof Naj Rahman	Dr Matt Rowland	Prof Brian Angus	Dr Nick Talbot
Intervention(s)	Synairgen inhaled IFNB	Infliximab namilumab	Remdesivir	Almetrine
Study size	101	120	1,063	116
Status	Complete	Complete	Complete	ongoing

Interventional studies in hospitalised patients (CTIMPS)

Clinical Trial or study evaluating the safety or efficacy of a drug (Investigational Medicinal Product - CTIMP)

Phase 3

Study name	RECOVERY	Synairgen phase 3 (Sprinter)	HEAL-COVID	REMAP CAP
Local Principal Investigator	Dr Katie Jeffery	Prof Najib Rahman	Dr Brian Angus	Dr Matt Rowland
Intervention(s)	Multiple Interventions <u>Welcome — RECOVERY Trial</u>	Synairgen inhaled IFNB	Atorvastatin Apixiban	Multiple interventions <u>REMAP-CAP Trial</u>
Study size	>39,000 patients recruited	610	1,000	International platform, thousands

Community / primary care studies linked to OUH/OU

Population	Healthcare workers at risk	Primary care patients at risk	ED attendees not admitted	ED attendees not admitted
Study name	COPCOV	PRINCIPLE	ATOMIC 2	Spike
Local PI	Dr Charlie Woodrow	Prof Chris Butler	Dr Tim Hinks	Dr Suzie Anthony
Intervention(s)	Hydroxychloroquine (HCQ)	Multiple interventions Join the PRINCIPLE Trial — PRINCIPLE Trial	Azithromycin	Camostat
Study size	600 in UK	3,000	160	389
Main question	In follow-up	Ongoing	Complete	In set-up

Observational studies

Study	Principal investigator
The Oxford Acute Myocardial Infarction Study	Prof Keith Channon
An observational study evaluating the haematological changes caused by COVID-19 infection and their association with thrombotic clinical outcomes	Dr Nicola Curry
A prospective non interventional study to evaluate the role of immune and inflammatory response in recipients of allogeneic haematopoietic stem cell transplantation (SCT) affected by severe COVID19 infection	Dr Andrew Peniket
Biomarker Investigation & Study of Pathology in Neuropathy (BioSPIN)	Dr Simon Rinaldi
ISARIC/WHO Severe Acute Respiratory Infection Biological Sampling Study	Prof Brian Angus
The GAinS investigators: application of an integrated immune -omic approach in sepsis	Dr Stuart McKechnie
Tissue-resident memory T-cell (TRM) response in severe Community Acquired Pneumonia (ImmuneCAP Study): An observational pilot study	Dr Christopher Andersen
Genetics of susceptibility and mortality in critical care (GenOMICC)	Dr Stuart McKechnie
The impact of COVID-19 on patients with AML undergoing chemotherapy: an epidemiological study.	Prof Paresh Vyas
OCTAVE: Observational Cohorts Trial - T-cells Antibodies and Vaccine Efficacy in SARS-CoV-2	Prof Eleanor Barnes

Study	Principal investigator
Coagulopathy associated with Covid 19	Dr Susie Shapiro
PHOSP-COVID Post-hospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes	Prof Najib Rahman
Demographic, multi-morbidity and genetic impact on myocardial involvement and its recovery from COVID-19: the COVID-HEART study	Dr Vanessa M Ferreira
MyeloidScan A longitudinal observational cohort study investigating the impact of COVID 19 infection on organ function in patients with myeloid blood cancers	Dr Onima Chowdhury
PROSECO - A UK multicentre prospective observational study evaluating COVID-19 vaccine immune responses in lymphoid cancer	Dr Graham Collins
C-MORE Capturing MultiORgan Effects of COVID-19	Dr Betty Raman